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Letters to the EditorAn autosomal dominant form of non-cirrhotic portal hypertension
To the Editor:
The familial aggregation idiopathic non-cirrhotic portal hyper-
tension (INCPH) has been previously described, however, there
have been no reports of Mendelian inheritance [1–5]. We
describe the ﬁrst case of autosomal dominant inheritance of
INCPH in a single family.
Fig. 1 demonstrates the autosomal dominant inheritance pat-
tern, including male-to-male transmission. I.6 suffered a fatal
variceal haemorrhage and may have also been affected. In this
patient however, secondary causes of portal hypertension could
not be excluded given the lack of a comprehensive medical
record. INCPH was diagnosed in all cases in accordance with cri-
teria proposed by Schouten [6], excluding II.1 who died prior to
liver biopsy being performed. The siblings and children of
affected family members have been screened with upper gas-
trointestinal endoscopies, hepatosplenic ultrasound and full
blood examination.
Case 1 – Proband
identical ﬁndings. The patient died prior to being waitlisted for
liver transplantation due to spontaneous intracranial haemor-
rhages aged 61.
Case 3
II.1 was the older sister of II.3 who suffered a fatal variceal haem-
orrhage aged 57. She did not undergo liver biopsy, however sero-
logical testing did not have evidence of secondary causes of
INCPH. She did not have any risk factors for cirrhosis.
Case 4
III.1 is the nephew of II.3 and is a 54-year old male currently on
the waiting list for liver transplantation for severe recurrent HE.
He was ﬁrst diagnosed with INCPH at age 27 following a variceal
haemorrhage. He was managed initially with endoscopic scle-
rotherapy and subsequently variceal band ligation. Liver biopsy
at the time excluded cirrhosis. He was stable for many years
before developing HE. He has no evidence of HPS.II.3, a 67-year old male was referred to our centre in 1999, then
aged 52, for liver transplantation assessment. He had been diag-
nosed with apparent cryptogenic cirrhosis at age 44, based on
ﬁndings of portal hypertension on computed tomography scan-
ning, in addition to splenomegaly, low-grade hepatic
encephalopathy (HE) and thrombocytopaenia. He had required
prophylactic endoscopic variceal band ligation for oesophageal
varices. He had reported that his older sister (II.1) and paternal
uncle (I.6) both had died of variceal haemorrhage. His father
(I.2) had also died of portal hypertensive complications in his ﬁfth
decade, however he had a history of transfusion-related chronic
hepatitis B infection.
Over a period of 7 years follow-up the patient developed hep-
atopulmonary syndrome (HPS), ascites and worsening HE and
subsequently underwent orthotopic liver transplantation aged
59. Portopulmonary hypertension was excluded on right-heart
catheterisation. INCPH was diagnosed on the explant hepatec-
tomy specimen. The patient remains well seven years post-trans-
plantation, without clinical evidence of recurrent portal
hypertension.
Case 2
II.4 was the younger sister of the proband and was referred for
liver transplantation assessment at age 53 for progressive HE
and HPS. She had been diagnosed with INCPH aged 29, after pre-
senting with recurrent gastro-oesophageal variceal haemorrhage,
which was managed with a lienorenal shunt. Intra-operative liver
biopsy at the time of her surgical shunt demonstrated changes
Case 5
IV.2 is a 29-year old male, who is the son of III.1. He was diag-
nosed with INCPH aged 22, after an oesophageal variceal haemor-
rhage. Liver biopsy demonstrated changes consistent with INCPH.
He continues to undergo regular endoscopic variceal surveillance
and is yet to develop other portal hypertensive complications.
The explant hepatectomy from II.3 (Fig. 2A–F) showed nodules
of regenerative hepatocytes surrounded by cords of atrophic
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Fig. 1. Autosomal dominant inheritance pattern of affected family members
with non-cirrhotic portal hypertension. ‘‘Possibly affected’’ denotes family
member with fatal variceal haemorrhage of unclear aetiology due to incomplete
medical record.consistent with INCPH. A repeat liver biopsy at age 53 revealed
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hepatocytes (nodular regenerative hyperplasia), with congestion.
The portal tracts were ﬁbrotic with scarred, obliterated or arteri-
alised portal veins, and slender portal-to-portal or incomplete
peri-portal ﬁbrous septa (incomplete septal cirrhosis).
Inﬂammation was negligible. Biliary changes and cholate stasis
were attributed to portal hypertensive biliopathy. Remote organ-
ised large portal vein thrombosis was favoured to be a secondary
complication contributing to progressive liver disease and the
need for transplantation. There were no other features to suggest
an alternative cause (e.g. steatosis). Taken in the clinical context,
these ﬁndings were consistent with a diagnosis of INCPH [7].
Review of extant core biopsy material from IV.2 and II.4 suggested
a similar pattern of changes (Fig. 2G and H). Reports of core biop-
sies from III.1 and II.4 describe ﬁndings in keeping with same
process.
To our knowledge, this is the ﬁrst report of autosomal domi-
nant INCPH. The phenotype of autosomal dominant INCPH
appears to have more severe portal hypertensive complications,
which are characterised by variceal haemorrhage, HE and HPS,
compared to previous series of INCPH [1,5,8–10]. The implication
of Mendelian inheritance of INCPH in this family is that there may
potentially be a single gene or small group of genes responsible for
the development of the disorder. Further studies are necessary to
investigate the genetic origins of this condition, which may even-
tually lead to the identiﬁcation of therapeutic targets for INCPH.
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Fig. 2. Liver explant histopathology from II.3 (A–F), core biopsy from II.4 (G)
and core biopsy from IV.2 (H). (A) Features of incomplete septal cirrhosis are
seen with portal ﬁbrous expansion and occasional delicate septa, but no well-
developed nodularity or advanced ﬁbrosis (trichrome stain, 40). (B) Small portal
tract with absent portal vein (trichrome, 200). (C) Portal tract containing
nodular ﬁbrous scar at the site of portal vein branch (H&E, 200). (D) Periportal
hyperplasia and zone 3 atrophy with congestion (H&E, 100). (E) Arterialised and
narrowed portal vein branch (H&E, 200). (F) Portal tract showing portal vein
ectasia / ‘‘shunt vessels’’ (H&E, 100). (G) Core biopsy from II.4 (aged 51) showing
zonal congestion and atrophy with periportal hyperplasia, features suggesting
nodular regenerative hyperplasia. There was also subtle architectural distortion,
but no ﬁbrosis (H&E, 200). (H) Core biopsy from IV.2 (aged 22) showing subtle
zones of atrophy and compression, with areas of regenerative hyperplasia, and
delicate portal/periportal septa (reticulin stain, 100). There were mildly
prominent portal vein branches at the periphery of some portal tracts, and one
large tract lacked an appropriately sized portal vein. There was no evidence of
established cirrhosis. (This ﬁgure appears in colour on the web.)
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Low ascitic ﬂuid protein does not indicate an increased
risk for spontaneous bacterial peritonitis in current cohorts
To the Editor:
We read with interest the results of a large multicenter trial on
risk factors for spontaneous bacterial peritonitis (SBP) by Terg
et al. in the Journal of Hepatology [1]. In their analysis including
95 patients with SBP, neither proton pump inhibitor use nor
the concentration of ascitic ﬂuid (AF) protein could be conﬁrmed
as a risk factor for SBP.
Low AF protein has been reported to predispose to SBP in
decompensated cirrhosis according to several studies [2–5] dat-
ing from 1986 to 1993. This association was attributed to a lack
of opsonic factors, since AF protein correlates with peritoneal
immunoglobulin concentration and complement activity [6,7].
During hospitalization, patients with AF protein 610 g/L devel-
oped SBP ten times more often than patients with higher AF pro-
tein concentrations in an analysis including 17 patients with SBP
[2]. Two prospective studies comprising 127 patients (13 with
SBP) [4] and 110 patients (28 with SBP) [5] conﬁrmed low AF pro-
tein concentration as an independent predictor of SBP. In addi-
tion, AF protein 610 g/L was shown to predict the recurrence of
SBP [3]. Thus, current guidelines recommend the measurement
of AF protein to identify patients at high risk for SBP [8].
Given the discrepancies of available data, we here report the
results of a post-hoc analysis from two prospectively collected
registries of patients with cirrhosis and ascites undergoing para-
centesis in two German tertiary centers comprising 683 patients,
of whom 220 had SBP. Among 347 patients receiving paracentesis
with AF protein measurement between 12/2007 and 07/2014 in
the Jena University Hospital, 13 patients presented with a docu-
mented history of SBP more than 30 days before inclusion and 81
patients presented with SBP at baseline or during follow-up. In
the Bonn University Hospital, 336 patients with liver cirrhosis
received baseline paracentesis with AF protein measurement
between 05/2006 and 09/2013. Of these patients, 51 had a history
of SBP while 75 developed SBP at baseline paracentesis or during
follow-up. In both cohorts, AF protein concentrations were simi-
lar for patients who never had SBP and patients who developed
SBP (Table 1). When patients were stratiﬁed according to a cut-
off of less than 10 g/L or less than 15 g/L AF total protein, frequen-
cies were comparable between the SBP and non-SBP group.
In line with previous ﬁndings that AF protein does not change
during and after SBP [9], restricting the analysis to patients with-
out a history of SBP did not alter the results. AF protein in
patients with SBP at baseline (Jena: 15 g/L, interquartiles: 9–20,
p = 0.33; Bonn: 11 g/L, 8–20, p = 0.86) and AF protein in patients
with a ﬁrst episode of SBP during follow-up (Jena: 12 g/L, 8–20,
p = 0.93; Bonn: 12 g/L, 7–23, p = 0.54) did not differ from patients
who never had SBP (Jena: 12 g/L, 8–20; Bonn: 11 g/L, 7–18).
We can only speculate about the causes that underlie the fail-
ure to replicate the association between SBP and AF protein,
which has been reported in several studies more than 20 years
ago. Based on the data of the ﬁrst report on low AF protein as a
risk factor for SBP [2], the power to detect a signiﬁcant difference
between the groups exceeded 80% for each of our cohorts by far.
It is probable that changed epidemiology and/or different treat-
ments for cirrhosis play a major part. We can exclude the wide-
spread use of antibiotic prophylaxis, since Terg et al. [1] did not
include patients receiving antibiotic prophylaxis, only 2.3% of
the patients in the Jena cohort and 1.5% of the patients in the
Bonn cohort received long-term primary prophylaxis with quino-
lones or cotrimoxazol. Changes in diuretic therapy may also
account for the discrepancies. Diuretics have been shown to
improve AF opsonic activity to a greater degree than the protein
concentration [10], which may reduce the correlation of AF pro-
tein with opsonic activity and therefore diminish its role as a
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